Ex-EPA Official Heads New Institute On Health Risks

PASADENA, CALIF.—An industry-funded research institute that pledges to be independent of the companies that are funding it is the latest player in the debate on, the environmental and public health risk of toxic chemicals. The Institute for Evaluating Health Risks (IEHR) says it is the nation’s first independent institute formed to specifically address environment-related health risks. It was put together by ethicist Charles Powers, a former philosophy professor at Yale Universi

Written byKathyrn Phillips
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

PASADENA, CALIF.—An industry-funded research institute that pledges to be independent of the companies that are funding it is the latest player in the debate on, the environmental and public health risk of toxic chemicals.

The Institute for Evaluating Health Risks (IEHR) says it is the nation’s first independent institute formed to specifically address environment-related health risks. It was put together by ethicist Charles Powers, a former philosophy professor at Yale University, who has started two other organizations for evaluating environmental problems.

IEHR’s origins lie in a 1986 California law known as Proposition 65, which bars industry from releasing toxic substances into waterways and requires industry to warn consumers of the levels of toxic chemicals contained in products. Exempt from the law are substances that have been shown to pose no significant risk, a formidable challenge for any manufacturing company.

This fall the institute moved into an office at the National ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies